PreCardia is a medical technology company focused on developing advanced treatment solutions for Acute Decompensated Heart Failure (ADHF). Serving primarily healthcare providers and hospitals, PreCardia operates within the cardiovascular medical device market. The company's core product, the preCARDIA System, is an investigational device designed to manage ADHF by temporarily occluding the superior vena cava (SVC) to reset the heart's function. This approach targets the hemodynamic instability that is common in ADHF patients, aiming to improve patient outcomes during hospitalization. PreCardia generates revenue through the development and eventual commercialization of its medical devices, relying on clinical trials and regulatory approvals to bring its products to market. The company was incubated by MD Start and is headquartered in St. Paul, Minnesota.

Keywords: ADHF, hemodynamic targets, superior vena cava, heart failure, medical technology, cardiovascular, investigational device, clinical trials, healthcare providers, hospitalization.